28 Mar 2022 15:09
For immediate release
28 March 2022
ABCAM PLC
("Abcam" or the "Company")
Block Listing application of Ordinary Shares
Cambridge, UK : Abcam plc (AIM: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has applied for a block admission for a further 4,350,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to be admitted to trading on AIM on 29 March 2022. This will be used to facilitate the admission of shares to trading following the exercise of options granted under the following two share schemes:
· Abcam Growth Plan - 3,500,000 shares;
· Annual Bonus Plan - 850,000 shares.
The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.
New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.
At the time of this announcement, Abcam plc has 228,908,563 Ordinary Shares in issue.
Date of Notification: 28 March 2022
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Marc Perkins, Company Secretary
| |
Numis - Nominated Adviser & Joint Corporate Broker | + 44 (0) 20 7260 1000 |
Garry Levin / Freddie Barnfield / Duncan Monteith | |
Morgan Stanley - Joint Corporate Broker Tom Perry / Luka Kezic |
+44 (0) 20 425 8000 |
FTI Consulting Ben Atwell / Natalie Garland-Collins |
+44 (0) 20 3727 1000 |
Notes to Editors
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information, please visit corporate.abcam.com .